Join Now

Category Archives: BioUtah News

Vocal Biomarkers: Helping Clinicians Detect What Patients Hesitate to Share

By Henry O’Connell, Canary Speech Five years into caring for a patient, a primary care physician saw her again shortly after she delivered her first child. The visit was scheduled as a routine six-week newborn evaluation. As is common in primary care, the encounter extended beyond the infant to include the mother’s well-being. During the […]

| Comments Off on Vocal Biomarkers: Helping Clinicians Detect What Patients Hesitate to Share

University of Utah Earns Dual Recognition in Global and U.S. Patent Rankings

Author: Amanda Ashley, Director of Communications for Research & Innovation, Office of the Vice President for Research The University of Utah has been named to the National Academy of Inventors’ (NAI) 2025 Top 100 U.S. Universities Granted U.S. Utility Patents list, further reinforcing its position as a national leader in research, innovation, and commercialization. This […]

| Comments Off on University of Utah Earns Dual Recognition in Global and U.S. Patent Rankings

Merit Medical Acquires View Point Medical, Inc., expanding the Merit Therapeutic Oncology Portfolio

SOUTH JORDAN, Utah, April 01, 2026 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced it has acquired View Point Medical, Inc. (View Point). Through a merger transaction, View Point is now a wholly-owned subsidiary of Merit. View Point, located in Carlsbad, California, manufactures the OneMark® Detection […]

| Comments Off on Merit Medical Acquires View Point Medical, Inc., expanding the Merit Therapeutic Oncology Portfolio

CancerVax Reports Successful Initial Mouse Study with Breakthrough Results

First biodistribution study of the Company’s novel targeted lipid nanoparticle achieved systemic circulation with the potential to target many types of cancer Lehi, Utah, March 31, 2026 – CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform that uses the body’s immune system to treat cancer, today announced that the initial biodistribution study […]

| Comments Off on CancerVax Reports Successful Initial Mouse Study with Breakthrough Results

TWO YEAR DATA ON EDWARDS LIFESCIENCES’ EVOQUE SYSTEM CONTINUE TO DEMONSTRATE SIGNIFICANT AND SUSTAINED PATIENT BENEFITS

TRISCEND II randomized trial data presented at ACC show lower mortality with EVOQUE system, when accounting for patient crossover NEW ORLEANS–(BUSINESS WIRE)– Edwards Lifesciences (NYSE: EW) today announced new data on the EVOQUE transcatheter tricuspid valve replacement (TTVR) system at the American College of Cardiology Annual Scientific Session (ACC.26), demonstrating significant and sustained patient benefits […]

| Comments Off on TWO YEAR DATA ON EDWARDS LIFESCIENCES’ EVOQUE SYSTEM CONTINUE TO DEMONSTRATE SIGNIFICANT AND SUSTAINED PATIENT BENEFITS

SINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle Implant

Via OrthoSpineNews   Major clinical milestone marks SINTX’s entry into the foot and ankle reconstruction market and advances commercialization of its silicon nitride biomaterial platform SALT LAKE CITY, Utah, March 19, 2026 (GLOBE NEWSWIRE) — SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced ceramic biomaterials and silicon nitride medical device innovation, […]

| Comments Off on SINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle Implant

Co-Diagnostics Joint Venture CoMira Receives Approval for Manufacturing Facility in Kingdom of Saudi Arabia’s Sudair Industrial City

Facility in Sudair Industrial City is expected to position CoMira among the early domestic manufacturers of molecular diagnostic testing solutions in Saudi Arabia SALT LAKE CITY, April 2, 2026 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (“Co-Dx” or “the Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that CoMira […]

| Comments Off on Co-Diagnostics Joint Venture CoMira Receives Approval for Manufacturing Facility in Kingdom of Saudi Arabia’s Sudair Industrial City

Nelson Labs® Offers Rare Inside Look at Lab Expansion Designed to Help Protect Patient Safety

Salt Lake City–based laboratory opens normally restricted space to invited guests, highlighting the behind‑the‑scenes work that helps keep medicines and medical products safe   SALT LAKE CITY (April 1, 2026) — Nelson Labs, a Salt Lake City–founded global leader in laboratory testing services, recently hosted invited guests for a rare look inside a new cleanroom […]

| Comments Off on Nelson Labs® Offers Rare Inside Look at Lab Expansion Designed to Help Protect Patient Safety

Fluidx Medical Announces First Patient Treated with Novel Embolic Gel

Gel embolic device designed to simplify the embolization procedure and reduce risks to the patient.

| Tagged | Comments Off on Fluidx Medical Announces First Patient Treated with Novel Embolic Gel

BioUtah Presents at Medical Korea 2026

BioUtah president & CEO, Kelvyn Cullimoire, was invited by the Korean Health Industry Development Institute (KHIDI), an agency of the Korean Ministry of Health, to present at the Medical Korea conference on March 19-20, 2026. The topic of Cullimore’s presentation was “Why Utah is a preferred landing place for Korean medical device companies desiring to […]

| Comments Off on BioUtah Presents at Medical Korea 2026

BioUtah CEO, Kelvyn Cullimore, Makes the Rounds in DC

BioUtah CEO, Kelvyn Cullimore, Makes the Rounds in DC

| Tagged | Comments Off on BioUtah CEO, Kelvyn Cullimore, Makes the Rounds in DC

Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)

First new FDA-approved treatment option in nearly 20 years for families living with this rare lysosomal storage disease.

| Tagged | Comments Off on Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)